EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors

Rafael Madero-Marroquin iD, Adam S DuVall, Caner Saygin, Peng Wang, Sandeep Gurbuxani, Richard A Larson, Wendy Stock, Anand Ashwin Patel iD

British Journal of Haematology · 2024-04 · 204 (4) · 1238-1242

DOI: 10.1111/bjh.19250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 10.12.2023. Verfasst von Rafael Madero-Marroquin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Aminopyridines, Aniline Compounds. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Data regarding the use of FMS‐like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in acute lymphoblastic leukaemia (ALL) are lacking. We identified 14 patients with FLT3 ‐ or IDH 1/2 ‐mutated ALL. Three early T‐cell precursor‐ALL patients received FLT3 or IDH2 inhibitors. Patient 1 maintains a complete remission (CR) with enasidenib after intolerance to chemotherapy. Patient 2 maintained a CR for 27 months after treatment with enasidenib for relapsed disease. Patient 3 was treated with venetoclax and gilteritinib at the time of relapse and maintained a CR with gilteritinib for 8 months. These cases suggest that FLT3 and IDH inhibitors could represent a viable therapeutic option for ALL patients with these mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteAminopyridinesAniline CompoundsPyrazinesTriazinesHumansfms-Like Tyrosine Kinase 3Neoplasm Recurrence, LocalEnzyme InhibitorsMutation

Stichwörter der Autor:innen

ALLFLT3IDH1IDH2targeted

Substanzen

gilteritinibenasidenibfms-Like Tyrosine Kinase 3Enzyme InhibitorsFLT3 protein, humanAminopyridinesAniline CompoundsPyrazinesTriazines

Autor:innen und Institutionen

  • Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
  • Department of Pathology, University of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Rafael Madero-Marroquin, Anand Ashwin Patel

Zitieren

APA

Madero-Marroquin, R., DuVall, A. S., Saygin, C., Wang, P., Gurbuxani, S., Larson, R. A., Stock, W., & Patel, A. A. (2024). Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. British Journal of Haematology, 204(4), 1238-1242. https://doi.org/10.1111/bjh.19250

Vancouver

Madero-Marroquin R, DuVall AS, Saygin C, Wang P, Gurbuxani S, Larson RA, et al. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. British Journal of Haematology. 2024;204(4):1238-1242. doi:10.1111/bjh.19250

BibTeX
@article{MaderoMarroquin2024,
  author = {Madero-Marroquin, Rafael and DuVall, Adam S and Saygin, Caner and Wang, Peng and Gurbuxani, Sandeep and Larson, Richard A and Stock, Wendy and Patel, Anand Ashwin},
  title = {Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {204},
  number = {4},
  pages = {1238--1242},
  doi = {10.1111/bjh.19250}
}
Kostenlos starten →